Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
NRG Oncology
UroGen Pharma Ltd.
Aarhus University Hospital
Mayo Clinic
National Cancer Center, Korea
Hospital Centre Biel/Bienne
UroGen Pharma Ltd.
Tongji Hospital
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)